Soligenix Inc. (NASDAQ: SNGX) announced that it has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) for its pipeline product dusquetide in the treatment of Behçet’s disease. This opinion is a critical step toward orphan drug designation by the European Commission, which would provide incentives including protocol assistance, reduced regulatory fees, and up to 10 years of market exclusivity following approval.
Behçet’s disease is a rare, chronic inflammatory disorder that affects blood vessels throughout the body, causing ulcers in the mouth and genitals, skin lesions, and inflammation in the eyes, joints, and nervous system. Current treatments often involve immunosuppressants, which can have significant side effects. Dusquetide is classified as an innate defense regulator, a type of compound designed to modulate the body’s innate immune system rather than suppress it outright. This novel mechanism of action could offer a new therapeutic option for patients with unmet medical needs.
“We are extremely pleased to have received the positive opinion from the COMP and look forward to the European Commission granting the orphan drug designation for the SGX945 program,” said Soligenix CEO and president Christopher J. Schaber, PhD. “The EMA’s positive opinion signifies an important step for Soligenix as we continue to advance the program.”
Orphan drug designation is intended to encourage the development of treatments for rare diseases affecting fewer than 5 in 10,000 people in the European Union. For patients living with rare inflammatory diseases, such regulatory milestones can mark the difference between stalled research and meaningful therapeutic progress. A positive opinion from the EMA not only validates a drug’s scientific rationale but can also unlock development incentives that accelerate its path forward.
Soligenix is a late-stage biopharmaceutical company focused on developing treatments for rare diseases and areas of unmet medical need. The company’s pipeline includes other candidates in oncology and biodefense. The positive opinion for dusquetide adds momentum to Soligenix’s development efforts. For more information, visit the company’s newsroom at https://ibn.fm/SNGX.
This development underscores the potential of dusquetide to address an area of significant unmet medical need. With the regulatory pathway in Europe becoming clearer, Soligenix is well-positioned to advance dusquetide through clinical trials and potentially bring a new therapy to patients suffering from Behçet’s disease.
